Overview

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Bristol-Myers Squibb
Onconova Therapeutics, Inc.
Treatments:
Nivolumab
ON 01910